PMID- 33809984 OWN - NLM STAT- MEDLINE DCOM- 20210430 LR - 20210430 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 22 IP - 6 DP - 2021 Mar 22 TI - Cleavage of the Perlecan-Semaphorin 3A-Plexin A1-Neuropilin-1 (PSPN) Complex by Matrix Metalloproteinase 7/Matrilysin Triggers Prostate Cancer Cell Dyscohesion and Migration. LID - 10.3390/ijms22063218 [doi] LID - 3218 AB - The Perlecan-Semaphorin 3A-Plexin A1-Neuropilin-1 (PSPN) Complex at the cell surface of prostate cancer (PCa) cells influences cell-cell cohesion and dyscohesion. We investigated matrix metalloproteinase-7/matrilysin (MMP-7)'s ability to digest components of the PSPN Complex in bone metastatic PCa cells using in silico analyses and in vitro experiments. Results demonstrated that in addition to the heparan sulfate proteoglycan, perlecan, all components of the PSPN Complex were degraded by MMP-7. To investigate the functional consequences of PSPN Complex cleavage, we developed a preformed microtumor model to examine initiation of cell dispersion after MMP-7 digestion. We found that while perlecan fully decorated with glycosaminoglycan limited dispersion of PCa microtumors, MMP-7 initiated rapid dyscohesion and migration even with perlecan present. Additionally, we found that a bioactive peptide (PLN4) found in perlecan domain IV in a region subject to digestion by MMP-7 further enhanced cell dispersion along with MMP-7. We found that digestion of the PSPN Complex with MMP-7 destabilized cell-cell junctions in microtumors evidenced by loss of co-registration of E-cadherin and F-actin. We conclude that MMP-7 plays a key functional role in PCa cell transition from a cohesive, indolent phenotype to a dyscohesive, migratory phenotype favoring production of circulating tumor cells and metastasis to bone. FAU - Tellman, Tristen V AU - Tellman TV AD - Department of Diagnostic and Biomedical Sciences, School of Dentistry, The University of Texas Health Science Center at Houston, 7500 Cambridge Street Room 4401, Houston, TX 77054, USA. FAU - Cruz, Lissette A AU - Cruz LA AD - Department of Diagnostic and Biomedical Sciences, School of Dentistry, The University of Texas Health Science Center at Houston, 7500 Cambridge Street Room 4401, Houston, TX 77054, USA. FAU - Grindel, Brian J AU - Grindel BJ AD - Department of Diagnostic and Biomedical Sciences, School of Dentistry, The University of Texas Health Science Center at Houston, 7500 Cambridge Street Room 4401, Houston, TX 77054, USA. AD - Department of BioSciences, Weiss School of Natural Sciences, Rice University, Houston, TX 77005, USA. FAU - Farach-Carson, Mary C AU - Farach-Carson MC AUID- ORCID: 0000-0002-4526-3088 AD - Department of Diagnostic and Biomedical Sciences, School of Dentistry, The University of Texas Health Science Center at Houston, 7500 Cambridge Street Room 4401, Houston, TX 77054, USA. AD - Department of BioSciences, Weiss School of Natural Sciences, Rice University, Houston, TX 77005, USA. AD - Center for Theoretical Biological Physics, Rice University, Houston, TX 77005, USA. LA - eng GR - P01CA0989-12/CA/NCI NIH HHS/United States GR - RP160015/Cancer Prevention and Research Institute of Texas/ GR - RP170593/Cancer Prevention and Research Institute of Texas/ PT - Journal Article DEP - 20210322 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (Cell Adhesion Molecules) RN - 0 (Nerve Tissue Proteins) RN - 0 (persephin) RN - 0 (plexin) RN - 144713-63-3 (Neuropilin-1) RN - EC 3.4.24.23 (MMP7 protein, human) RN - EC 3.4.24.23 (Matrix Metalloproteinase 7) SB - IM MH - Cell Adhesion MH - Cell Adhesion Molecules/metabolism MH - Cell Line, Tumor MH - Cell Movement MH - Fluorescent Antibody Technique MH - Humans MH - Male MH - Matrix Metalloproteinase 7/*metabolism MH - Models, Biological MH - Nerve Tissue Proteins/*metabolism MH - Neuropilin-1/metabolism MH - Prostatic Neoplasms/etiology/*metabolism MH - Protein Binding MH - Proteolysis PMC - PMC8004947 OTO - NOTNLM OT - dyscohesion OT - matrilysin/MMP-7 OT - microtumors OT - migration OT - perlecan/HSPG2 OT - prostate cancer COIS- The authors declare no conflict of interest. EDAT- 2021/04/04 06:00 MHDA- 2021/05/01 06:00 PMCR- 2021/03/22 CRDT- 2021/04/03 01:34 PHST- 2021/02/05 00:00 [received] PHST- 2021/03/15 00:00 [revised] PHST- 2021/03/15 00:00 [accepted] PHST- 2021/04/03 01:34 [entrez] PHST- 2021/04/04 06:00 [pubmed] PHST- 2021/05/01 06:00 [medline] PHST- 2021/03/22 00:00 [pmc-release] AID - ijms22063218 [pii] AID - ijms-22-03218 [pii] AID - 10.3390/ijms22063218 [doi] PST - epublish SO - Int J Mol Sci. 2021 Mar 22;22(6):3218. doi: 10.3390/ijms22063218.